AACR 2023 Poster 4679

Molecular Pathology and BTKi Pharmacology of DLBCL PDX Models

Jingjing Wang¹, Yueying Wang¹, Wubin Qian¹, Jia Xue¹, Sheng Guo¹, Likun Zhang¹, Henry Li<sup>2

1</sup>Crown Bioscience, Inc., San Diego, California, USA
²Hanx Biopharmaceuticals Inc., Oceanside, California, USA

Diffuse large B cell lymphoma (DLBCL), the largest subtype of non-Hodgkin’s lymphoma (NHL), ~40%, is a heterogeneous disease with diverse pathogenesis. Epstein-Barr Virus positive DLBCL (EBV+ DLBCL) has also been recognized as a distinct subtype by WHO, originated from clonal B cell lymphoid proliferation, likely driven by EBV infection, which results in viral oncoprotein-induced transformations. BTK plays an exclusive and vital role in B cell development, and ibrutinib is a first-in class, orally-administered, selective and covalent BTK inhibitor (BTKi), approved for treating several B cell lymphomas, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), but not yet for DLBCL. With the complexity of clinical trials, patient-derived xenografts (PDXs) become an alternative and powerful experimental system to investigate heterogeneous molecular pathology, and their corresponding pharmacology of DLBCLs.

Download this Poster to Discover:

• Creation of an unique PDX cohort representative of diverse subtypes of de novo DLBCL patients, along with 15 EBV transformed DLBCLs during xenografting
  
  
• Molecular pathology analysis of the DLBCL PDX cohort
  
  
• BTKi pharmacology response for EBV- and EBV+ DLBLC PDX

Download the Poster Now!